Azaya Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Phase 1
- Conditions
- Ovarian CancerCancerOvarian TumorMalignant Female Reproductive System NeoplasmOvarian Epithelial Cancer Recurrent
- Interventions
- Drug: DOXIL/CAELYXDrug: ATI-0918
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Azaya Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01715168
- Locations
- 🇨🇦
Centre Hospitalier de L'Universite de Montreal (CHUM), Montreal, Quebec, Canada
🇺🇸Yakima Valley Memorial Hospital - North Star Lodge, Yakima, Washington, United States
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Phase 1
Completed
- Conditions
- Ovarian CancerSolid TumorBreast CancerPancreatic CancerNon-Small Cell Lung
- Interventions
- Drug: ATI-1123 (active drug = docetaxel)
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Azaya Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01041235
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
🇺🇸Cancer Therapy and Research Center (CTRC), San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath